Orkambi

Department of Health written question – answered on 24th March 2017.

Alert me about debates like this

Photo of Tracy Brabin Tracy Brabin Labour, Batley and Spen

To ask the Secretary of State for Health, what discussions he has had with Vetrex and NHS England on the drug Orkambi's availability to people with cystic fibrosis.

Photo of Tracy Brabin Tracy Brabin Labour, Batley and Spen

To ask the Secretary of State for Health, what assessment he has made of the potential merits of making the drug Orkambi availabile to people with cystic fibrosis.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

Ministers and Government officials have had a number of discussions with Vertex and NHS England in which the availability of Orkambi for the treatment of cystic fibrosis was raised.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops guidance for the National Health Service on whether new drugs and treatments represent a clinically and cost effective use of resources.

NICE published final guidance on the use of Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis homozygous for the F508del mutation in July 2016 that does not recommend this treatment.

Where NICE has not been able to recommend a treatment, funding decisions should be made by the relevant NHS commissioner, based on an assessment of the available evidence.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.